ArticleJournal of translational medicine2025
ELF3-regulated PES1 targets VEGFR2 to mediate angiogenesis and retinal inner barrier injury in diabetic retinopathy.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis and increased vascular permeability caused by endothelial cell dysfunction are crucial in diabetic retinopathy (DR). Pescadillo ribosomal biogenesis factor 1 (PES1) plays key roles in diabetes; however, its effect on DR has not been thoroughly investigated. This study evaluated the role of PES1 in angiogenesis and blood-retinal barrier functions of DR and explored the related regulatory mechanisms.
methodsIntegrated bulk RNA-seq and single-cell RNA-seq analyses were used to identify the key molecular target PES1 in this study. Western blot, scratch assay, tube formation assay, transwell, EdU proliferation assay, immunofluorescence, Evans Blue assay, PAS staining and H&E staining were used to detect the role of PES1 in angiogenesis and retinal barrier injury in vivo and in vitro, respectively. ChIP-seq was used to explore the regulatory mechanism.
resultsIntegrated bulk RNA-seq and single-cell RNA-seq analyses revealed that high PES1 expression was significantly associated with DR. Under hyperglycemia conditions, elevated PES1 expression disrupted the retinal vascular barrier function and exacerbated vascular leakage and DR progression by inhibiting the expression of VE-cadherin and Occludin. Moreover, PES1 aggravated the imbalance between oxidation and anti-oxidation, leading to an excessive release of reactive oxygen species and further impairment of endothelial cell function. These biological processes were reversed by PES1-targeted siRNA/shRNA. Mechanistically, PES1 bound to the enhancer of VEGFR2 to regulate VEGFR2 mRNA expression, thereby influencing tube formation capacity and permeability of endothelial cells. Under diabetic conditions, PES1 upregulation was regulated by ELF3 binding to its promoter.
conclusionsOur study confirmed that the ELF3/PES1/VEGFR2 signaling pathway is crucial for regulating retinal angiogenesis and blood-retinal barrier function in DR. Interventions targeting ELF3 or PES1 may serve as potential therapeutic strategies for DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.